Bombyx Batryticatus Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is the dried, milled and controlled preparation of Bombyx mori larvae infected with Beauveria bassiana (Bals.-Criv.) Vuill., intended as an active pharmaceutical ingredient in veterinary dosage forms. The material is not a single-molecule chemical entity but a multicomponent crude drug matrix containing polysaccharides, beauvericin, bassianolide, chitin-derived fragments and insect-derived lipids; therefore its release profile depends on particle-size distribution, residual moisture, total ash and marker-compound consistency rather than on a single assay value. Supplier-specific model codes are not harmonized under a pharmacopoeial monograph. A representative coding convention distinguishes D90 ≤ 75 µm powder for oral solid dosage forms, D90 ≤ 25 µm micronized material for injectable suspensions, and gamma-irradiated powder for aseptic granulation. Each lot is accompanied by a certificate of analysis listing moisture, ash, heavy metals and microbial limits. Storage is specified at 15–25 °C and relative humidity below 60 %, with re-test intervals commonly set at 24 months when the primary container is closed and protected from light.

When the crude drug is characterized as a veterinary active ingredient rather than a dietary additive

Characterization begins with botanical identity by macroscopic and microscopic examination against the monograph for Bombyx Batryticatus in the Chinese Veterinary Pharmacopoeia. Infrared fingerprinting and thin-layer chromatography for beauvericin are used to distinguish authentic infected larvae from non-infected white silkworm powder. The purity controls are expressed as total ash, acid-insoluble ash and extractable matter. Representative release limits are total ash ≤ 7.0 %, acid-insoluble ash ≤ 2.0 %, and ethanol-soluble extractive ≥ 20.0 %. Heavy-metal screening by USP <233> inductively coupled plasma-mass spectrometry yields a control limit of ≤ 20 mg/kg for lead, ≤ 2 mg/kg for cadmium, ≤ 2 mg/kg for arsenic, and ≤ 0.5 mg/kg for mercury. Food-grade powder batches in the same supply chain may be released under looser mycotoxin and microbial criteria, while the veterinary API grade must demonstrate absence of specified pathogens and controlled elemental impurities.

Across all seven dosage-form routes, the powder is initially de-agglomerated in a low-shear blender equipped with an intensifier bar. High-shear mixing is reserved for wet granulation batches; prolonged high-shear exposure above 300 rpm for more than 20 minutes increases dust generation and can alter the chitin matrix by frictional heating. In direct compression, the API is typically loaded at 5–25 wt% with microcrystalline cellulose, spray-dried lactose and sodium starch glycolate. Blend uniformity is measured by sampling 10 locations across a V-blender after 15 minutes; acceptance is ≤ 5.0 % relative standard deviation for beauvericin content. The material’s poor flow, often characterized by a Carr index of 28–35, necessitates glidant addition at 0.5–1.0 wt% colloidal silicon dioxide for capsule filling. For hard gelatin capsules, a fill weight of 0.4–0.7 g is common, but published data for this specific configuration is limited; dissolution testing in 0.1 M hydrochloric acid at 37 ± 0.5 °C with paddle speed 50 rpm should not be assumed to reflect release of all marker compounds because the matrix contains both water-soluble and poorly soluble fractions.

Wet granulation for tablets and granules uses 5 % w/v povidone K30 in purified water as the binder solution. The endpoint is determined by torque or impeller power draw rather than visual inspection; a target wet-mass density of 1.2–1.4 g/mL is typical but must be validated for each batch. Drying in a fluid-bed dryer with inlet air at 50–60 °C and product temperature not exceeding 40 °C is preferred; tray drying above 60 °C can produce case-hardened granules and non-uniform residual moisture. For premix preparation, the API is step-lubricated with a carrier of defatted rice hulls or precipitated calcium carbonate; segregation potential increases when the carrier particle size exceeds 10× the D90 of the API. Inclusion rates in medicated premixes are formulation-specific and should be justified by stability-indicating assays rather than extrapolated from human-dose publications.

Why are injectable and solution dosage forms assigned a different powder fraction than oral solid and premix use?

Injectable preparations of Bombyx Batryticatus Veterinary Grade API are generally produced as aqueous extracts rather than as raw-powder suspensions. Direct incorporation of milled whole larva into an injection is not a recognized pharmaceutical practice because chitin fragments and fungal conidia cannot be rendered sterile and pyrogen-free by terminal steam sterilization without destroying thermolabile constituents. For injectable solutions, the drug path is a water extraction at 80–90 °C for 1–2 hours, followed by refrigerated settling at 2–8 °C for not less than 12 hours, centrifugation, and sequential filtration through 0.45 µm and 0.22 µm membranes. Filter-loading effects require validation of membrane surface area; a pressure drop above 0.25 MPa indicates premature fouling. Injectable-grade powder entering extraction should have a D90 not greater than 50 µm to increase extraction efficiency; the final solution is not assayed for particle size but for bacterial endotoxins by USP <85> and sterility by USP <71>. Published data for the endotoxin limit of this specific veterinary extract is limited; a specification of < 0.5 EU/mg is often applied as a conservative input if the product is intended for systemic administration, but toxicological justification must be documented for the target species.

For oral solutions, the extraction ratio is typically 1:10 w/v with purified water at 85 °C for 1.5 h. The decoction is concentrated under vacuum at 60–70 °C to a relative density of 1.05–1.10 g/mL at 20 °C. After cooling, ethanol precipitation at 60 % v/v precipitates high-molecular-weight proteins; the supernatant is recovered and residual ethanol removed under vacuum to < 0.5 %. The final solution is adjusted to total solids 5–10 % w/v and filtered. Stability is limited by polysaccharide hydrolysis in acidic media; pH should remain above 4.5. Oral solutions and drenches can be stabilized with a citric acid/sodium citrate buffer at pH 5.5–6.5. Potassium sorbate at 0.1 % w/v is often tested as a preservative, but no harmonized veterinary monograph stability data exists for this crude drug extract.

Assessing batch-to-batch variation using marker assays and chromatographic fingerprints

Quantitative analysis of beauvericin is performed by reversed-phase HPLC with a C18 column 150 mm × 4.6 mm, 5 µm, mobile phase acetonitrile-0.1 % formic acid 70:30 v/v, flow rate 1.0 mL/min, column temperature 30 °C, and detection at 220 nm. The marker content is expressed as µg/g crude drug. Published inter-laboratory reproducibility for this specific matrix is limited; in-house precision should meet RSD ≤ 3 % for peak area and RSD ≤ 1 % for retention time. Total polysaccharide content is measured by phenol-sulfuric acid colorimetry using glucose as standard; because polysaccharide composition is heterogeneous, the result is a conventional expression rather than an absolute quantification. Chromatographic fingerprint similarity against a reference batch is required to be not less than 0.90, calculated by the cosine similarity of the common peak-area vector. This criterion rejects adulterated or substituted Bombyx mori larval powder, which may show similar macroscopic appearance but different fungal-metabolite profiles.

On a 500 L ribbon blender with ribbon-to-shell clearance of 2–5 mm, batch-to-batch blend uniformity failures for low-dose premixes occur when the API is added directly as a top layer; step dilution with 1:1 and 1:3 geometric stages is required. The torque trajectory of a high-shear granulator with a 10 L bowl, impeller speed 200–300 rpm and chopper 1500 rpm is used to define the granulation endpoint. Field observations indicate that adding binder solution faster than 25 mL/min per kg of dry mass creates oversized granules with D50 above 1200 µm and poor tablet hardness uniformity. For tablet compression on a rotary press, precompression force 3–5 kN and main compression 15–25 kN are typical; friability should be ≤ 1.0 %. These values are not pharmacopoeial specifications but process-development reference points.

Compendial control points and batch release specifications

Differentiation from food-grade Bombyx batryticatus powder lies principally in microbial and elemental controls. Food-grade powder may be released with total aerobic counts of 10⁵ CFU/g and without Salmonella testing, whereas veterinary API grade applies 10³ CFU/g and obligates absence of Salmonella in 10 g. Different from a human-grade crude drug lot, the veterinary-grade batch may permit a wider total ash band but must document the absence of specified animal-derived processing aids under veterinary residue rules. Different from synthetic low-molecular-weight veterinary APIs such as phenylbutazone or flunixin meglumine, this raw material has no single melting point or chromatographic purity; batch-to-batch variation in beauvericin content is controlled as a marker range rather than an absolute assay. This distinction matters for formulation scientists because standard high-performance liquid chromatography methods suitable for small molecules must be revalidated for matrix interference from fungal metabolites and insect-derived lipids.

Process limitations include heat sensitivity and hygroscopicity. Pre-drying is required when relative humidity exceeds 65 % during open handling. The powder should not be combined with strongly alkaline granulating agents because chitin and residual protein fractions degrade at pH above 9 and may produce amine-like off-odors. Ethylene oxide sterilization requires desorption validation because the porous matrix can retain residual gas; documented desorption curves are necessary. If sterilization is required, validated gamma irradiation at 10–20 kGy is preferred, but published data on marker stability after irradiation of this specific matrix is limited. Batch records should document re-milling if particle size shifts during storage.

Long-term stability data for the dried API in sealed aluminium-foil bags at 25 °C ± 2 °C / 60 % RH ± 5 % RH over 24 months show no more than 15 % loss of beauvericin content; accelerated data at 40 °C ± 2 °C / 75 % RH ± 5 % RH for 6 months are used only for temporary extension. The powder darkens under light exposure, and the ethanol-soluble extractive can increase as moisture uptake promotes enzymatic degradation of residual insect tissue. Therefore photoprotection and desiccant use in primary packaging are critical. Stability assessment follows VICH GL18 for veterinary drug substances; long-term 25 ± 2 °C / 60 % RH ± 5 % RH and accelerated 40 ± 2 °C / 75 % RH ± 5 % RH are the reference conditions for Zone II climates. For dry premix formulations in moisture-barrier liners, the product is expected to remain within specification for 12–24 months; data from liquid oral solutions are less robust, and published data for this specific configuration is limited.